Flow Pharma, Inc., Warrensville Heights, OH, USA.
Case Western Reserve University, Cleveland, OH, USA.
Commun Biol. 2023 Mar 18;6(1):288. doi: 10.1038/s42003-023-04687-4.
SARS-CoV-2 has extensively mutated creating variants of concern (VOC) resulting in global infection surges. The Omicron VOC reinfects individuals exposed to earlier variants of SARS-CoV-2 at a higher frequency than previously seen for non-Omicron VOC. An analysis of the sub-lineages associated with an Omicron primary infection and Omicron reinfection reveals that the incidence of Omicron-Omicron reinfections is occurring over a shorter time interval than seen after a primary infection with a non-Omicron VOC. Our analysis suggests that a single infection from SARS-CoV-2 may not generate the protective immunity required to defend against reinfections from emerging Omicron lineages. This analysis was made possible by Next-generation sequencing (NGS) of a Danish cohort with clinical metadata on both infections occurring in the same individual. We suggest that the continuation of COVID-19 NGS and inclusion of clinical metadata is necessary to ensure effective surveillance of SARS-CoV-2 genomics, assist in treatment and vaccine development, and guide public health recommendations.
SARS-CoV-2 广泛变异产生了令人关注的变种(VOC),导致了全球感染浪潮。奥密克戎 VOC 比以前非奥密克戎 VOC 更容易重新感染先前接触过 SARS-CoV-2 早期变种的个体。对奥密克戎初次感染和奥密克戎再感染相关亚谱系的分析表明,奥密克戎-Omicron 再感染的发生率比初次感染非奥密克戎 VOC 后的时间间隔更短。我们的分析表明,单次感染 SARS-CoV-2 可能不会产生对抗新兴奥密克戎谱系再感染所需的保护性免疫。这项分析是通过对丹麦队列进行下一代测序(NGS)实现的,该队列具有两次感染的临床元数据,均发生在同一个体中。我们建议继续进行 COVID-19 NGS,并纳入临床元数据,以确保对 SARS-CoV-2 基因组学进行有效监测,协助治疗和疫苗开发,并指导公共卫生建议。